Fedratinib: First Approval
Compliance with Ethical Standards
Funding The preparation of this review was not supported by any external funding.
Conflicts of interest During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
information about this Adis Drug Review can be found here.
is a JAK2-selective inhibitor that has been developed as an oral treatment for
myelofibrosis. In August 2019, fedratinib received
its first global approval in the USA for the treatment of adult patients with
intermediate-2 or high-risk primary or secondary (post-polycythemia vera or
post-essential thrombocythemia) myelofibrosis. Phase III clinical
development for myelofibrosis is ongoing worldwide. This article summarizes the
milestones in the development of fedratinib leading to this first approval for
© Springer Nature Switzerland AG 2019